633317-81-4

Basic information

• Product Name: 1-(4-Chlorophenyl)cyclopropanecarbohydrazide
• Synonyms: 1-(4-Chlorophenyl)cyclopropanecarbohydrazide
• CAS NO: 633317-81-4
• Molecular Formula: C₁₀H₁₁ClN₂O
• Molecular Weight: 210.66014
• Mol File: 633317-81-4.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(4-Chlorophenyl)cyclopropanecarbohydrazide(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-Chlorophenyl)cyclopropanecarbohydrazide(633317-81-4)
• EPA Substance Registry System: 1-(4-Chlorophenyl)cyclopropanecarbohydrazide(633317-81-4)

Safety Data

• Hazardous Substances Data: 633317-81-4(Hazardous Substances Data)

Upstream product

• 72934-37-3 3-(4-chlorophenyl)-1-cyclopropanecarboxylic acid 
• 117252-05-8 methyl 1-(4-chlorophenyl)cyclopropane-1-carboxylate 

Downstream Products

• 1024614-40-1 5-[1-(4-chlorophenyl)cyclopropyl]-3H-1,3,4-oxadiazol-2-one 
• 1403396-04-2 (8R)-8-({[tert-butyl(dimethyl)silyl]oxy}methyl)-3-[1-(4-chlorophenyl)cyclopropyl]-8-methyl-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepine 
• 1403396-00-8 (8S)-8-({[tert-butyl(dimethyl)silyl]oxy}methyl)-3-[1-(4-chlorophenyl)cyclopropyl]-8-methyl-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepine 
• 1403395-95-8 8-({[tert-butyldimethylsilyl]oxy}methyl)-3-[1-(4-chlorophenyl)cyclopropyl]-8-methyl-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepine 
• 1403395-16-3 {8-methyl-3-[1-(2'-methylbiphenyl-4-yl)cyclopropyl]-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepin-8-yl}methanol 
• 1403395-15-2 {8-methyl-3-[1-(3'-methylbiphenyl-4-yl)cyclopropyl]-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepin-8-yl}methanol 
• 1403395-14-1 4'-{1-[8-(hydroxymethyl)-8-methyl-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepin-3-yl]cyclopropyl}-N,N-dimethylbiphenyl-3-carboxamide 
• 1403395-13-0 5-(4-{1-[8-(hydroxymethyl)-8-methyl-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepine-3-yl]cyclopropyl}phenyl)-N,N-dimethylpyridine-2-carboxamide 
• 1403396-09-7 5-(4-{1-[8-({[tert-butyl(dimethyl)silyl]oxy}methyl)-8-methyl-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepine-3-yl]cyclopropyl}phenyl)-N,N-dimethylpyridine-2-carboxamide 
• 1403395-11-8 4'-{1-[8-(hydroxymethyl)-8-methyl-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepin-3-yl]cyclopropyl}-N,N-dimethylbiphenyl-4-carboxamide 
• 1403396-07-5 4'-{1-[8-({[tert-butyl(dimethyl)silyl]oxy}methyl)-8-methyl-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepine-3-yl]cyclopropyl}-N,N-dimethylbiphenyl-4-carboxamide 
• 1403395-10-7 {8-methyl-3-[1-(4-pyridin-4-ylphenyl)cyclopropyl]-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepine-8-yl}methanol 
• 1403396-06-4 8-({[tert-butyl(dimethyl)silyl]oxy}methyl)-8-methyl-3-[1-(4-pyridin-4-ylphenyl)cyclopropyl]-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepine 
• 1403395-09-4 {(8R)-8-methyl-3-[1-(4-pyridin-3-ylphenyl)cyclopropyl]-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepin-8-yl}methanol 

Relevant articles and documents

TETRAHYDROTHIAZEPINE DERIVATIVE

The present invention relates to a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof having an excellent effect of inhibiting 11β-hydroxysteroid dehydrogenase type 1: General formula (I) wherein R1 represents a phenyl group that may be substituted with 1 to 5 group(s) independently selected from substituent group A or a heterocyclic group that may be substituted with 1 to 4 group(s) independently selected from substituent group A; R2 independently represents a halogen atom or a C1-C6 alkyl group; n represents an integer of 0 to 2; and substituent group A represents the group consisting of halogen atoms, C1-C6 alkyl groups, and so forth.

11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA

Compounds having Formula (I), including pharmaceutically acceptable salts, hydrates and solvates thereof, are selective inhibitors of the 11β-HSD1 enzyme. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dylsipidemia, hyperlipidemia, hypertension, Syndrome X, and other symptoms associated with NIDDM.